National Institute of Environmental Health Sciences (NIEHS)
Background: The SARS-CoV-2 virus has caused a pandemic. Little is known about the virus, so data is needed to form an effective public health response. Researchers want to count how many people have been exposed to COVID-19, learn about symptoms, and find out how many antibodies to the SARS-CoV-2 virus a person may have in their blood over 1 year. This data could affect the response to current and future pandemics. Objective: To learn how many people from a sampling of adults in North Carolina develop antibodies to the SARS-CoV-2 virus over 1 year. Eligibility: Healthy people age 18 and older who do not currently have COVID-19 Design: Participants will be screened with questions about their health. Participants will have five 30-minute visits at the Clinical Research Unit. At each visit, they will have blood drawn to see if they have SARS-CoV-2 antibodies. If the test result is positive for antibodies, the participant will be tested to see if they currently have COVID-19. For this, a nasal or throat swab will be done, or saliva will be collected. They may do this test at the same visit as the blood draw, or they may schedule an extra visit. Around the time of their study visits, participants will take an online survey about themselves, their health, and COVID-19. It takes 10 minutes to complete. Every week for 52 weeks, they will also take a brief online survey about their symptoms. It takes 2 minutes to complete. They will be emailed a link to log in and fill out the surveys on a secure website. Participation will last for 1 year. ...
COVID-19
It has been demonstrated that respiratory virus outbreaks and pandemics, such as influenza, SARS, MERS, and now the newly emerged SARS-CoV-2 virus, have a major impact on morbidity and mortality worldwide, as well as having devastating global economic and societal impact. During these outbreaks it is critical to gain a rapid understanding of the exposures and immunity in the general population. Identifying exposures can be accomplished through analysis of serum during an outbreak to identify those with specific antibodies to the pathogen.The knowledge of the level of exposures could greatly impact the response to current and future pandemics. This study is a prospective, longitudinal, observational, single-center, exploratory, natural history study to collect samples and data from individuals to identify the presence and rate of development of anti-SARS-CoV-2 antibodies in North Carolina. Objectives: Primary Objective: To characterize the proportion of people with detectable antibodies to SARS-CoV-2 from a sampling of adults in North Carolina. Exploratory Objectives: * To identify the incidence of newly detectable antibodies to SARS-CoV-2 in the recruited cohort of adults in North Carolina over 12 months after enrollment * To identify the rate of asymptomatic carriers of SARS-CoV-2 (PCR positive) among participants with detectable antibodies to SARS-CoV-2 * To associate presence or absence of detectable antibodies to SARS-CoV-2 with respiratory symptoms and future diagnosis with COVID-19 * To determine the natural history of antibody titers among the participants who are found to have detectable antibodies * To associate demographic and medical factors with incidence of newly detectable antibodies to SARS-CoV-2 Endpoints: Primary Endpoint: - Detection of Anti-SARS-CoV-2 antibodies by ELISA Assay Algorithm Exploratory Endpoints: 1. SARS-CoV-2 PCR of nasal swabs and correlation with serology 2. Clinical questionnaire data and correlation with serology and PCR
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 643 participants |
Official Title : | Serological Surveillance for COVID-19 in Central North Carolina |
Actual Study Start Date : | 2020-08-24 |
Estimated Primary Completion Date : | 2023-12-05 |
Estimated Study Completion Date : | 2023-12-05 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 100 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
NIEHS Clinical Research Unit (CRU)
Research Triangle Park, North Carolina, United States, 27709